Press Releases
Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
Dec 15, 2022
Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements
Dec 14, 2022
Tiziana Life Sciences Announces Date of Annual General Meeting 2022
Dec 06, 2022
Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects
Nov 23, 2022
Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)
Nov 10, 2022
Tiziana Life Sciences to Host Investor Call
Nov 04, 2022
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
Nov 03, 2022
Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
Nov 02, 2022
Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
Oct 26, 2022
Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference
Oct 19, 2022
Displaying 51 - 60 of 468